Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVL-865 High dose · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CVL-865 High dose | DRUG | High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day) |
| Alprazolam 1mg XR | DRUG | Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day) |
| Placebo | DRUG | Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day) |
| CVL-865 low dose | DRUG | Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day) |
CVL-865 High dose is an investigational small molecule being studied for the treatment of Panic Disorder. It is currently in Phase 1 clinical development, with a completed trial evaluating its effect on panic symptoms induced by carbon dioxide inhalation in healthy subjects.
CVL-865 High dose is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is in Phase 1 clinical development for Panic Disorder.
CVL-865 High dose is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is being studied for Panic Disorder.
CVL-865 High dose has one completed clinical trial, registered as NCT04592536. The trial, titled 'A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects,' enrolled 56 participants and was a Phase 1 study in Panic Disorder.
CVL-865 High dose is a specific dose level of the drug CVL-865. The clinical trial NCT04592536 evaluates the effect of CVL-865 on panic symptoms, and the high dose is one of the dose levels studied in this Phase 1 trial for Panic Disorder.